NASDAQ:ALLO | Free Cash Flow | Allogene Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2018-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$12.91M$9,000.00-$12.92M
2025-12-31-$27.6M$0.00-$27.6M
2025-03-31-$52.93M$99,000.00-$53.03M
2024-12-31-$36.7M$257,000.00-$36.96M
2024-03-31-$55.9M$8,000.00-$55.91M
2023-12-31-$53.71M$181,000.00-$53.89M
2023-03-31-$66.64M$1.04M-$67.67M
2022-12-31-$62.1M$1.69M-$63.79M
2022-03-31-$68.24M$1.9M-$70.14M
2021-12-31-$45.44M$736,000.00-$46.17M-53688.37%
2021-03-31-$49.33M$6.46M-$55.79M
2020-12-31-$9.98M$17.4M-$27.38M
2020-03-31-$40.81M$12.25M-$53.06M
2019-12-31-$50.27M$14.11M-$64.38M
2019-03-31-$30.26M$10.42M-$40.68M
2018-12-31-$21.48M$1.32M-$22.8M
2018-03-31$5,000.00$0.00$5,000.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$149.25M$386,000.00-$149.63M
2024-12-31-$200.3M$694,000.00-$200.99M
2023-12-31-$237.73M$1.52M-$239.25M
2022-12-31-$220.52M$5.19M-$225.71M
2021-12-31-$184.81M$21.45M-$206.26M
2020-12-31-$115.09M$65.96M-$181.05M
2019-12-31-$137.35M$50.79M-$188.14M
2018-12-31-$44.65M$3.23M-$47.89M